Is McKesson Corporation (NYSE:MCK) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating McKesson Corporation at current levels.
Boring distributor on the outside, GLP-1 and oncology toll-collector on the inside, with $5.7B free cash flow funding the compounding.
Where MCK is headed
By fiscal 2028, McKesson is no longer the sleepy pharma wholesaler it gets categorized as. The Oncology & Multispecialty segment, anchored by US Oncology Network and the Florida Cancer Specialists deal, becomes the highest-margin pillar of the business and the one analysts argue about on calls. Specialty drug volume, GLP-1s, oncology biologics, gene therapy through InspiroGene, runs through McKesson's distribution network at a scale that makes Cardinal and Cencora look like the junior partners they have effectively become in specialty. Revenue base around $390B, operating income closer to $6.5B, and a free cash flow run-rate north of $6B feeding buybacks that take the share count meaningfully below 120 million.
Read the full Compass Direction on MCK
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $754.68).
See the full MCK analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is McKesson Corporation (NYSE:MCK) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating McKesson Corporation at current levels. Boring distributor on the outside, GLP-1 and oncology toll-collector on the inside, with $5.7B free cash flow funding the compounding.
What is MCK's Compass Score?
McKesson Corporation scores 74/100 on Alexandria's Compass, placing it in the "Favorable" tier. Scores blend eight factors and update weekly.
What is the price target for MCK?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the MCK page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.